Telix to acquire ITM Isotope; deal value reported between $1.65 billion and $2.35 billion
Australian pharmaceutical company Telix Pharmaceuticals announced its agreement to acquire Germany-based ITM Isotope Technologies Munich SE. While the acquisition itself is confirmed, the reported financial terms vary significantly across outlets, ranging from $1.65 billion to $2.35 billion. This strategic move aims to enhance Telix's supply of radioisotopes.
3 articles from 3 outlets covered this story. Their coverage differs on 2 points. The underlying claim is sourced from a press release.
What do all outlets agree on?
3 outlets covered “Telix to acquire ITM Isotope; deal value reported between $1.65 billion and $2.35 billion”. All of them report the following:
- Telix Pharmaceuticals to acquire ITM Isotope Technologies Munich SE
- Telix is an Australian company
- ITM is a German company
- Acquisition aims to strengthen radioisotope supply
Did outlets disagree about this?
Yes. Coverage of “Telix to acquire ITM Isotope; deal value reported between $1.65 billion and $2.35 billion” differs on 2 points. Each account below is how a different outlet described the same event:
Total acquisition value
Impact on Telix's share price
Which figures do outlets report differently?
1 figure in this story is reported with conflicting values:
Which outlets covered this?
All 3 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.